Toll-like receptor 2 (TLR2) is a member of the TLR family of receptors that play a central role in innate immunity. In addition to regulating effector immune cells, where it recognizes a wide variety of pathogen-associated and nonpathogen-associated endogenous ligands, TLR2 is expressed in hematopoietic stem cells (HSCs). Its role in HSCs, however, is not well understood. Furthermore, augmented TLR2 signaling is associated with myelodysplastic syndrome, an HSC disorder characterized by ineffective hematopoiesis and a high risk of transformation to leukemia, suggesting that aberrant signaling through this receptor may have clinically significant effects on HSCs. Herein, we show that systemic exposure of mice to a TLR2 agonist leads to an expansion of bone marrow and spleen phenotypic HSCs and progenitors, but a loss of HSC self-renewal capacity. Treatment of chimeric animals shows that these effects are largely cell non-autonomous, with a minor contribution from cell-autonomous TLR2 signaling, and are in part mediated by granulocyte colony-stimulating factor and tumor necrosis factor-α. Together, these data suggest that TLR2 ligand exposure influences HSC cycling and function via unique mechanisms from TLR4, and support an important role for TLR2 in the regulation of HSCs.
INTRODUCTION
Toll-like receptors (TLRs) are pattern recognition receptors that play a central role in innate immunity. Recent reports suggest that TLR signaling regulates not only effector immune cells, but may also influence hematopoietic stem cells (HSCs). HSCs express multiple TLRs, 1, 2 and in vitro exposure to TLR agonists stimulates HSC cycling and skews HSC differentiation toward the myeloid lineage. [1] [2] [3] Furthermore, chronic treatment of mice with the TLR4 agonist lipopolysaccharide leads to HSC cycling and expansion, but decreased repopulating activity. 4, 5 Together, these studies suggest that TLR signaling may shape the immune response from the level of the HSC, regulating the proliferation, differentiation and activity of these cells, and chronic exposure to TLR signals may impair HSC function.
Although accumulating reports support a role for TLR signaling in regulating HSCs, the mechanism of these effects is not clear. TLRs are expressed on many hematopoietic and stromal cell types, and therefore systemic TLR ligand exposure could have direct or indirect effects on HSCs. Indeed, proinflammatory cytokines are produced by effector immune cells and hematopoietic progenitors in response to TLR ligands, 6 and such cytokines themselves can influence HSC cycling and function. 7 In addition, it is not known whether HSCs respond similarly to stimulation of different TLRs. The existing literature has largely focused on TLR4, with recent studies showing that TLR4 ligation indirectly promotes HSC mobilization via production of granulocyte colony-stimulating factor (G-CSF) by endothelial cells. 8, 9 It is not clear how stimulation of other TLR family members affects HSCs, and whether they similarly promote G-CSF-mediated HSC mobilization.
In this study, we sought to elucidate the effects of systemic TLR2 ligand exposure on HSCs and determine the cell-autonomous versus non-autonomous effects of such exposure. We specifically focused on TLR2 signaling, as although TLR2 is expressed on HSCs, 1, 10 its role in regulating these cells is not clear. Furthermore, multiple studies have identified increased TLR expression and signaling (particularly TLR2) in the CD34+ cells of patients with myelodysplastic syndromes (MDS), a group of hematopoietic stem cell disorders associated with ineffective hematopoiesis and a high risk of leukemic transformation. [11] [12] [13] [14] [15] This fact supports the idea that TLR2 may regulate HSCs, and aberrant signaling through this receptor may have clinically significant effects on HSCs. In fact, a clinical trial using a TLR2 antagonist for the treatment of patients with MDS is currently underway (Opsona Therapeutics, Dublin, Ireland), and thus an understanding of the role of TLR2 signaling in regulating HSCs is highly relevant toward advancing therapy for patients with MDS.
We and others previously reported that TLR2 is not necessary for HSC function (in fact, loss of TLR2 leads to improved bone marrow repopulating activity). 16, 17 Herein, we show that augmented TLR2 signaling via exposure of mice to the TLR2 agonist, PAM 3 CSK 4 , leads to an expansion of phenotypic bone marrow and spleen hematopoietic stem and progenitors (HSPCs), but a loss of bone marrow HSC function. Treatment of chimeric animals demonstrates that these effects are largely cell non-autonomous. Given the known role of G-CSF in mobilizing HSCs in response to TLR4 agonist, 8 we assessed the contribution of G-CSF to the effects of PAM 3 CSK 4 treatment on HSCs. Whereas PAM 3 CSK 4 treatment is associated with increased serum G-CSF levels, loss of G-CSF signaling only partially mitigates the agonist-induced effects on HSCs. Further studies demonstrated that tumor necrosis factor-α (TNFα) significantly contributes to the TLR2 agonist-mediated cycling and expansion of spleen HSCs. Notably, inhibition of G-CSF in chimeric mice revealed a cell-autonomous role for TLR2 signaling in expanding phenotypic HSCs as well. Together, these data demonstrate that systemic exposure to a TLR2 ligand influences HSCs via both cell-autonomous and non-autonomous mechanisms, and reveal key differences between the effects of different TLR agonists on HSCs. 
MATERIALS AND METHODS

Flow cytometry for HSPC and chimerism analysis
Peripheral blood was obtained by retro-orbital venous plexus sampling. Bone marrow was isolated by centrifugation of leg bones at 3300 g for 1 min. Spleen cells were harvested by crushing through a 100 μM strainer. Cells were processed as previously described, 18 and stained using the antibodies listed in Supplementary Materials. Cell counts were determined using a Countess automated cell counter (Invitrogen, Carlsbad, CA, USA). Stained cells were analyzed on a BD flow cytometer (BD, Franklin Lakes, NJ, USA) or the Gallios flow cytometer (Beckman Coulter, Indianapolis, IN, USA). Data were analyzed with FlowJo software (version 9.7; TreeStar, Ashland, OR, USA).
Cell cycle analysis
For Ki-67 staining, bone marrow or spleen cells were stained for surface markers (see Supplementary Materials), fixed using the BD cytofix/cytoperm kit (BD), blocked with 5% goat serum, stained with mouse anti-human Ki-67 (clone B56; BD Pharmingen, San Diego, CA, USA), washed and resuspended in DAPI (4',6-diamidino-2-phenylindole)-containing FACS buffer. For analysis of 5-bromodeoxyuridine (BrdU) incorporation, mice were injected with BrdU (1 mg intraperitoneally q12h × 4 doses) starting 48 h before cell harvest. Cells were stained for surface markers, and then fixed and stained for anti-BrdU using the FITC BrdU flow kit (BD) according to the manufacturer's instructions.
Long-term repopulating assays
For transplants involving sorted HSCs, bone marrow cells were obtained by crushing bones in phosphate-buffered saline with 0.1% bovine serum albumin. Spleens were gently crushed. Cells were filtered and stained using the panel of antibodies described in Supplementary Materials. c-Kit+ cells were enriched before sorting by selection with biotin-conjugated beads (Miltenyi Biotec, San Diego, CA, USA). Non-viable cells were excluded by DAPI staining. Twenty KSL SLAM donor HSCs were transplanted via retro-orbital injection, in addition to 3 00 000 recipient-type whole bone marrow support cells, into lethally irradiated recipient mice (2 doses of 550 cGy spaced 4 h apart). For whole bone marrow and whole spleen cell transplants, 1 × 10 6 bone marrow cells or 2 × 10 6 spleen cells were transplanted along with 1 × 10 6 bone marrow competitor cells into irradiated recipients.
Chimera generation
Chimeric mice were generated by transplanting a 1:1 mixture of whole bone marrow cells from wild-type (WT) and Tlr2 −/− donors into either WT or Tlr2 −/− recipients, as indicated. For Figure 4 , WT or Tlr2 −/− bone marrow was transplanted alone into either WT or Tlr2 −/− recipients. A total of 2 × 10 6 cells were injected retro-orbitally into lethally irradiated recipients. In all cases, cells were allowed to engraft for at least 11 weeks before treatment, and peripheral blood sampling of all chimeras was done before further analyses to ensure equal engraftment.
Homing assay 2 × 10 6 whole bone marrow cells were harvested from WT CD45.2 mice treated with PAM 3 CSK 4 (100 μg per dose, every 48 h × 3 doses) or water alone and transplanted via retro-orbital injection into lethally irradiated WT CD45.1 mice. After 16 h, long bones were harvested (pelvis, femur, tibia and humerii), crushed, filtered and stained for flow cytometry.
Cytokine measurements
Bone marrow was isolated by centrifugation of femurs and spleens were crushed through a 100 μm strainer. The total protein concentration was determined using the BCA Protein Assay (Pierce, Rockford, IL, USA). Blood was harvested by cardiac puncture, allowed to clot for 2 h, then spun for 10 min at 3300 g. Cytokine levels were determined using the Mouse Cytokine Array Panel A (R&D Systems) following the manufacturer's instructions. Membranes were exposed to X-ray film, and signal intensities were quantified with ImageJ (NIH, Bethesda, MD, USA). Serum G-CSF and TNFα levels were also measured using the mouse G-CSF quantikine enzyme-linked immunosorbent assay (ELISA) kit and the mouse TNFα quantikine ELISA kit, respectively (R&D Systems), following the manufacturer's instructions.
Colony forming units in culture assay
A total of 50 000 spleen cells were plated in MethoCult GF M3434 (Stem Cell Technologies, Vancouver, BC, Canada). Colonies were scored after 7 days of growth at 37°C in a humidified chamber with 5% CO 2 .
Statistical analysis
Data are presented as mean ± s.e.m., unless otherwise stated. Statistical significance was assessed using an unpaired, two-tailed Student's t-test or two-sided analysis of variance. Repopulating unit calculations were determined using the equation: RU = ([%chimerism of test donor-derived cells] × [no. of competitor cells] × 10 − 5 )/%chimerism of competitor-derived cells. 19 
RESULTS
TLR2 agonist treatment leads to expansion of bone marrow phenotypic HSCs but loss of BM repopulating activity TLR2 functions as a heterodimer with TLR1 or TLR6. 20 To determine the effects of systemic TLR2 agonist exposure on HSCs, WT mice were treated with the TLR1/2 agonist PAM 3 CSK 4 (3 doses of 100 μg intraperitoneally every other day). Bone marrow and spleen cells were harvested 24 h following the final dose and analyzed by flow cytometry (Supplementary Figure 1) . We observed a modest increase in the frequency of bone marrow HSCs (c-Kit+ Sca-1+ Lineage − CD150+ CD48 − cells, 'KSL SLAM' or c-Kit+ Lineage − CD150+ CD48 − ) and a decrease in megakaryocyte-erythroid progenitors 6 whole bone marrow cells from PAM 3 CSK 4 -treated mice or water controls were transplanted into lethally irradiated recipients. Shown are the total number of KSL cells detected from the long bones (femurs, tibias, humerii) and pelvis 16 h later (n = 5 mice per group). For all panels, error bars represent mean ± s.e.m., and P-values were determined by the two-tailed Student's t-test. Figures 2I and j) . Thus, functional HSCs increase in the spleen upon TLR2 agonist exposure.
TLR2 agonist effects on HSC expansion and function are, at least in part, cell non-autonomous As TLR2 is expressed on multiple hematopoietic and stromal cell populations in addition to HSCs, the effects of systemic TLR2 signaling regulates HSCs AC Herman et al TLR2 agonist treatment could be either cell autonomous or cell non-autonomous. A recent study demonstrated that exposure of mice to a TLR4 ligand mobilizes HSCs in a cell-non-autonomous, G-CSF-dependent manner. 8 To determine whether the effects of TLR2 signaling are similarly non-autonomous, we generated chimeric mice in which a 1:1 mixture of Tlr2 −/− (CD45.2) and WT (CD45.1) bone marrow cells were transplanted into WT recipients (Figure 3a ). Chimeras were treated as above with PAM 3 CSK 4 , and HSPCs were analyzed by flow cytometry. In addition, bone marrow from these mice was transplanted into new irradiated recipients to assess HSC function. We reasoned that if TLR2 signaling regulates HSCs in a cell-autonomous manner, we would observe a preferential effect of agonist treatment on WT cells, whereas if the effects of TLR2 ligation were non-autonomous, we would find a similar effect of treatment on both Tlr2 −/− and WT HSCs. Although there was not a significant increase in bone marrow HSCs from either population in these chimeras (Figures 3b and c) , PAM 3 CSK 4 treatment resulted in a marked increase in both WT and Tlr2 −/− HSPCs in the spleen (Figures 3d and e) , suggesting that the spleen expansion is mediated by extrinsic factors. In fact, we actually saw a preferential mobilization of Tlr2 −/− HSCs in our chimeras. The reason for this is unclear, however a similar phenomenon was reported for Tlr4
HSCs mobilized by Escherichia coli, 8 and we previously found that Tlr2
−/− HSCs mobilize more robustly than WT cells upon G-CSF exposure, suggesting that they may be more responsive to mobilizing stimuli. 16 To assess whether the loss of bone marrow repopulating activity is cell autonomous versus non-autonomous, we transplanted bone marrow from the treated chimeras into new irradiated recipients. Again, we reasoned that if the effects of TLR2 signaling on HSC function are cell autonomous, we would observe a preferential defect in the WT cells (that is, a decrease in %CD45.1 upon PAM 3 CSK 4 treatment), whereas if the effects of TLR2 ligation are non-autonomous, we would find a similar effect of treatment on both Tlr2
−/− and WT HSCs (that is, no difference in chimerism). Analysis of the peripheral blood chimerism of these secondary recipients showed no differences between treatment groups (Supplementary Figure 5) , suggesting that the functional deficit described in Figure 1 is influenced by non-autonomous TLR2 signaling. Thus, as the effects of PAM 3 CSK 4 on HSPCs are observed in cells lacking TLR2 as well as WT cells, these effects must be, at least in part, cell non-autonomous.
Spleen HSPC expansion upon TLR2 agonist exposure is mediated by non-autonomous effects of TLR2 signaling in both radioresistant and radiosensitive cell populations We next generated chimeras to determine whether stromal versus hematopoietic TLR2 signaling mediates HSPC expansion. Specifically, we transplanted WT bone marrow into Tlr2 −/− recipients (WT → Tlr2 ; Figure 4a) ; however, spleen HSPCs increased in all three chimeric groups (Figures 4b and c) , suggesting that TLR2 expression on either radioresistant (that is, mostly stromal) or radiosensitive (hematopoietic) cells is sufficient to induce some mobilization (or expansion) of spleen HSPCs.
TLR2 agonist treatment leads to G-CSF production by both radioresistant and radiosensitive cell populations To identify potential mediators of the cell-non-autonomous effects of TLR2 signaling on HSPCs, we performed cytokine arrays on WT mouse serum, bone marrow and spleen after systemic treatment with PAM 3 CSK 4 . Serum levels of G-CSF, CXCL13, IP-10/CXCL10 and monocyte chemoattractant protein (MCP-1/CCL2) were the most markedly increased in treated mice compared with controls (Supplementary Figure 6) . As noted above, recent reports have demonstrated that the TLR4 ligand lipopolysaccharide induces G-CSF production from endothelial cells, and G-CSF mediates the mobilization of HSCs in response to lipopolysaccharide. 8, 9 We therefore first considered that G-CSF may similarly mediate HSC mobilization in response to TLR2 agonist. Indeed, PAM 3 CSK 4 exposure is associated with a dose-dependent increase in serum G-CSF (Figure 5a ). Furthermore, we observed an increase in serum G-CSF in all of our chimeras (WT → WT, WT → Tlr2 −/− and Tlr2 −/− → WT), but not in parent Tlr2 −/− mice (Figure 5b ), suggesting that both radioresistant and radiosensitive cell populations serve as sources of this cytokine.
Suppression of G-CSF signaling partially mitigates the effects of TLR2 agonist exposure on HSPCs
To assess the contribution of G-CSF signaling to the effects of TLR2 agonist treatment on HSCs, we treated mice lacking the G-CSF receptor (Csf3r −/− mice) with PAM 3 CSK 4 . Although bone marrow HSCs expanded in response to PAM 3 CSK 4 in the absence of G-CSF signaling (Figures 5c and d) , loss of this signaling leads to a modest reduction in spleen myeloid progenitor cell expansion, specifically resulting in reduced expansion of spleen common myeloid progenitors, granulocyte-monocyte progenitors and myeloid progenitor colony-forming units in response to PAM 3 CSK 4 compared with WT (Figure 5f and Supplementary Figure 7) . A similar reduction in PAM 3 CSK 4 -mediated spleen myeloid progenitor expansion was observed when WT mice were treated with a G-CSF neutralizing antibody (Supplementary Figure 7) . Of note, we still observed a significant increase in spleen HSCs and progenitors in the absence of G-CSF signaling (Figure 5e and Supplementary Figure 7) , suggesting that G-CSF is not the sole mediator of this increase. In fact, transplantation of whole spleen cells from mice treated with PAM 3 CSK 4 and G-CSF neutralizing antibody revealed no loss of total spleen repopulating units (Supplementary Figure 7) .
Cell-autonomous TLR2 signaling contributes to spleen HSC expansion As G-CSF only partially accounts for the expansion of spleen HSPCs in response to PAM 3 CSK 4 , other extrinsic factors, or cell-autonomous TLR2 signaling, must account for the remaining increase. To address whether there is a cell-autonomous component to this expansion, we treated chimeric mice (WT+Tlr2 (Figure 6b) , supporting a role for G-CSFindependent, hematopoietic-mediated non-autonomous TLR2 signaling in this process. However, we observed a relatively greater −/− controls were plated in complete methylcellulose media and myeloid colony formation was scored after 7 days of growth at 37°C (n = 3-4 mice per group). For all panels, error bars represent mean ± s.e.m., and P-values were determined by the two-tailed Student's t-test. Figure 5 . G-CSF production partially accounts for the effects of TLR2 agonist exposure on HSPCs. (a) WT mice (6-8 weeks old) were given a single intraperitoneal (i.p.) injection of PAM 3 CSK 4 at the indicated doses, and serum G-CSF levels were determined by ELISA 12 h later (n = 4-6 mice per treatment level). (b) Chimeric mice as described in Figure 4 were given a single i.p. injection of 100 μg PAM 3 CSK 4 , and serum G-CSF levels were determined by ELISA (n = 3 mice per group, with the exception of the water group (n = 9) that represents pooled controls from all of the treatment groups. (c) WT or Csf3r −/− mice were treated with PAM 3 CSK 4 (100 μg i.p. q48 h × 3 doses, analyzed 24 h after final dose). Shown are the frequency (c) and absolute numbers (d) of KSL SLAM cells in the bone marrow. Also shown are KSL SLAM cells per spleen (e). (f) Whole spleen cells from PAM 3 CSK 4 -treated mice or water-treated controls were plated on complete methylcellulose, and colonies counted after 7 days of growth at 37°C (n = 6-7 mice per group). For all panels, error bars represent mean ± s.e.m., and P-values were determined by the two-tailed Student's t-test. (Figure 6c ), suggesting that cell-autonomous TLR2 signaling contributes to HSC expansion. Thus, although PAM 3 CSK 4 clearly affects cells lacking TLR2 (reflecting indirect, or cell-non-autonomous effects), the more robust expansion of WT cells compared with Tlr2 −/− cells in this experiment demonstrates that cell-autonomous signaling also contributes to this effect of PAM 3 CSK 4 on HSCs.
TNFα contributes to the TLR2 agonist-mediated expansion of HSPCs in the spleen We next considered whether the other cytokines elevated upon PAM 3 CSK 4 treatment contribute to the remaining non-autonomous effects of TLR2 signaling on HSCs (Supplementary Figure 6) . To this end, we assessed the response of Ccl2 − / − , Cxcr5 − / − (CXCR5 is the receptor for CXCL13), IFNγ − / − and TNFα − / − mice to PAM 3 CSK 4 exposure. We assessed a small number of Cxcl10 −/− mice as well with no obvious difference in TLR2-mediated effects from WT (data not shown). As CXCL10 is regulated by interferon-γ (IFNγ) and TNFα, and these cytokines can regulate HSCs, [21] [22] [23] we tested their contribution as well (in fact, serum TNFα levels increased by ELISA upon PAM 3 CSK 4 treatment; Supplementary Figure 8) . Notably, loss of TNFα results in a significant decrease in the magnitude of the PAM 3 CSK 4 -mediated expansion of spleen HSCs and progenitors compared with WT (Figures 7b and c and Supplementary Figure 8) , and spleen HSC cycling in response to the TLR2 agonist is mitigated in the absence of TNFα (Figure 7d ). Furthermore, treatment of mice with neutralizing antibodies to both G-CSF and TNFα before PAM 3 CSK 4 injection reduced the expansion of HSCs in the spleen by nearly threefold, and markedly decreased spleen common myeloid progenitors, granulocyte-monocyte progenitors and progenitor colony-forming units (Figures 7e-g and Supplementary Figure 8) , further implicating these cytokines as regulators of spleen HSPC mobilization/expansion in response to TLR2 ligand.
DISCUSSION
Although multiple TLRs are expressed on HSCs, most notably TLR2 and TLR4, 10 most of the published studies have focused on the effects of TLR4 stimulation on HSCs. We recently reported that TLR2 is not necessary to maintain normal HSC function, 16 and herein we sought to determine the effects of systemic TLR2 ligand exposure on HSCs. Our data demonstrate that indeed TLR2 stimulation affects HSC expansion and function, and suggest that these effects are mediated by both cell-autonomous and cell-nonautonomous mechanisms.
Recent studies have shown that exposure of mice to systemic TLR4 ligands leads to HSC expansion and mobilization, and a loss of bone marrow HSC function. 4, 5, 8, 24, 25 Mechanistic studies indicate that TLR4 stimulation leads to G-CSF production from endothelial cells, 9 and G-CSF signaling blockade abrogates TLR4-induced HSC accumulation in the spleen. 8 Like TLR4, stimulation of TLR2 leads to HSPC expansion, loss of HSC function and G-CSF production. However, in response to TLR2 agonist, G-CSF is produced from both radioresistant and radiosensitive populations, suggesting it is not primarily endothelial in origin. In addition, suppression of G-CSF signaling only partly mitigates the expansion of myeloid progenitors in the spleen and does not significantly affect HSCs. Further studies demonstrated that TNFα contributes to the cell-non-autonomous effects of TLR2 agonist exposure on HSPCs. The identity of the cell types that mediate these non-autonomous effects await further studies using mice with conditional deletion of TLR2.
Our chimeric animal studies with G-CSF inhibition also support a role for cell-autonomous TLR2 signaling in the expansion of HSCs. Megias et al. 26 previously demonstrated that purified WT c-Kit+ Sca-1+ Lineage − HSPCs transferred into Tlr2 −/− -deficient recipients differentiate into macrophages in response to shortterm treatment with PAM 3 CSK 4 , suggesting that HSPCs can directly responding to TLR signals in vivo. Joo et al. 27 similarly demonstrated that WT c-Kit+ Lineage − HSPCs transplanted into Tlr2 −/− -deficient mice differentiated into myeloid lineage cells in response to TLR2 agonist. Together with prior in vitro studies demonstrating that TLR2 stimulation directs myeloid differentiation of HSPCs, 1, 3 our data reinforce the idea that TLR2 agonists have cell-autonomous effects on HSCs. These data highlight an important point that the effects of TLR signals on HSCs may differ depending on the particular agonist/TLR, with TLR4 signals exerting largely G-CSF-dependent, non-cell-autonomous effects on HSCs and TLR2 signals exerting primarily TNFα-dependent effects, with a more minor contribution from G-CSF and cellautonomous effects.
Interestingly, we find that, unlike bone marrow HSCs, spleen HSCs are significantly less quiescent upon TLR2 ligand exposure. Thus, in contrast to the primarily mobilization-mediated increase in spleen HSCs upon TLR4 ligation, 8 TLR2 signaling appears to stimulate local proliferation of spleen HSCs. This TLR2 agonistinduced spleen HSC cycling is lost in TNFα − / − mice, implicating TNFα in this process. The biologic significance of this local proliferation and the reason for the differential effects of TLR2 agonist exposure on the cycling of bone marrow versus spleen (e-g) WT mice were treated with PAM 3 CSK 4 as described above, and in addition some mice received G-CSF and TNFα neutralizing antibodies or isotype control antibody before PAM 3 CSK 4 injections. KSL SLAM cells in the bone marrow (e) and spleen (f) were determined by flow cytometry. In addition, whole spleen cells were plated on complete methylcellulose, and colonies counted after 7 days of growth at 37°C (g); n = 5-6 mice per group. For all panels, error bars represent mean ± s.e.m., and P-values were determined by the two-tailed Student's t-test.
HSCs is not known. Of note, Granick et al. 28 recently reported that proliferation of HSPCs in skin wounds in response to the TLR2 agonist Staphylococcus aureus contributes significantly to the production of neutrophils and resolution of local infection, supporting a role for TLR2 signaling in the regulation of extramedullary hematopoiesis.
The accumulating data on TLR agonist effects on HSCs suggest that TLR signals may, in the short term, influence HSC proliferation and differentiation to optimize the immune response to an acute insult. In theory, enhanced cycling, mobilization and differentiation of HSCs during acute infection could help to ensure that the proper cadre of effector cells are produced to eliminate the offending stimulus. Chronic or aberrant exposure to these signals, however, may lead to dysfunctional hematopoiesis and contribute to bone marrow failure or malignancy. Enhanced TLR2 signaling has recently been implicated in MDS. 15 Our data support a role for TLR2 signaling in the regulation of HSCs, with agonist exposure leading to expansion of HSCs in the bone marrow and spleen, but a reduction in HSC self-renewal. These findings suggest the possibility that enhanced TLR2 signaling may contribute to the ineffective hematopoiesis characteristic of MDS. The role of TLR2 signaling in this disease and the contribution of TLR2 signaling from different cell types to the effects of TLR2 agonist exposure on normal and premalignant HSCs awaits further study.
